MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Imatinib During Pregnancy May Cause Infant Abnormalities

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Imatinib During Pregnancy May Cause Infant Abnormalities




Imatinib During Pregnancy May Cause Infant Abnormalities
While doctors already face a number of challenges in treating patients with cancer, treating pregnant women with the disease, in particular, can be quite difficult as studies suggest that certain therapies can harm developing fetuses. As per the results of a study prepublished recently online in Blood, the official journal of the American Society of Hematology, expectant women treated with imatinib, a usually used treatment for chronic myeloid leukemia (CML), may be at moderate risk of developing fetal abnormalities.


Imatinib During Pregnancy May Cause Infant Abnormalities

Imatinib was introduced for the therapy of CML in 1998 and has become a primary treatment for most patients, turning the previously fatal disease into a mostly chronic condition in the last decade. The drug's label warns that women of child-bearing age should avoid pregnancy while taking the drug based on earlier studies that suggested it may penetrate the placenta and cause damage to developing cells.

The retrospective study evaluated records of 180 cases of CML therapy during pregnancy reported to Novartis, the Hammersmith Hospital in London, or The University of Texas M. D. Anderson Cancer Center to determine the real risks of imatinib treatment. Specific outcomes data were available for 125 of the cases, as 55 cases had incomplete pregnancy-related data.

Half of the pregnancies resulted in the birth of normal live infants (n=63). Thirty-five women underwent elective terminations, three following the identification of fetal abnormalities. At least 18 pregnancies resulted in miscarriage. The remainder of the births resulted in infants with congenital abnormalities (n=9, one still birth). In total, 12 pregnancies resulted in infants with fetal abnormalities (9.6 percent) and of those, there were eight live births, one still birth and three terminations (mentioned above). Some of the abnormalities in the infants were similar, including exomphalos (umbilical hernia), renal agenesis (undeveloped kidney), and hemivertebrae (underdeveloped spine). The stillborn child suffered from meningocoele (cerebral hernia).

The study showed that a significant proportion of pregnancies exposed to imatinib result in a normal outcome and a healthy infant. The miscarriage rate in the study was 14.4 percent, which is within the expected range for the general population. However, the fact that some of the abnormalities seen in the 12 infants were similar to results found in early animal studies with imatinib suggests the possibility of an imatinib-induced effect.

"Our study suggests that a concern about conceiving a child while taking imatinib is justified and that patients should be advised to avoid conception while on therapy," said Dr. Seonaid Pye, of the Department of Hematology, Imperial College of London and lead author of the study. "In those patients who do become pregnant, balancing the risk of the fetus from taking treatment to the risk of the mother from interrupting treatment will be an individual decision".

The majority of women in the study were being treated for CML at the time of conception; just four cases were exposed after the first trimester. The dose and the exact duration of imatinib treatment are unknown for most cases, with insufficient information to assess a dose-related relationship. There were no reports of maternal exposure to alcohol, drugs, or tobacco addiction during pregnancy, and none of the mothers had received other high-dose chemotherapy previous to their pregnancies.

"The risks and benefits to an expectant woman fighting cancer and her fetus are challenging and must be reviewed on an individual basis with careful counseling," said Dr. Pye. "Ultimately, the therapy of CML during pregnancy clearly remains a considerable clinical challenge".


Posted by: Janet    Source




Did you know?
While doctors already face a number of challenges in treating patients with cancer, treating pregnant women with the disease, in particular, can be quite difficult as studies suggest that certain therapies can harm developing fetuses. As per the results of a study prepublished recently online in Blood, the official journal of the American Society of Hematology, expectant women treated with imatinib, a usually used treatment for chronic myeloid leukemia (CML), may be at moderate risk of developing fetal abnormalities.

Medicineworld.org: Imatinib During Pregnancy May Cause Infant Abnormalities

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.